Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.55 |
| ▸ | CNR1 | P21554 | 7/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127886 | 0.87 | CNR1 (0.55) | TACR1CNR1CNR2TACR2 | |
| SCHEMBL1127425 | 0.82 | CNR1 (0.51) | TACR1CNR1CNR2TACR2 | |
| SCHEMBL1990424 | 0.82 | CNR1 (0.51) | TACR1CNR1CNR2TACR2 | |
| SCHEMBL1990009 | 0.81 | CNR1 (0.49) | TACR1CNR1CNR2TACR2 | |
| SCHEMBL1127599 | 0.81 | CNR1 (0.49) | TACR1CNR1CNR2TACR2 | |
| SCHEMBL5099220 | 0.81 | TACR1 (0.47) | TACR1CNR1CNR2CA12CA1 | |
| SCHEMBL1260389 | 0.79 | CNR1 (0.53) | TACR1CNR1CNR2CA12CA1 | |
| SCHEMBL5099240 | 0.79 | TACR1 (0.46) | TACR1CNR1CNR2CA12CA1 | |
| SCHEMBL1983795 | 0.79 | CNR1 (0.46) | TACR1CNR1CNR2TACR2 | |
| SCHEMBL1260541 | 0.77 | CNR1 (0.60) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | claimed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | claimed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | claimed |
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-08-14 | — | — | US | disclosed |
| US-7381727-B2 | Pyrrole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-03 | — | — | US | disclosed |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| EP-1781636-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006024777-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194581-A1 | PYRROLE DERIVATIVES, INTERMEDIATES THEREFOR, PREPARATION AND THERAPEUTIC USE THEREOF | PYCR1, FARS2, WEE1 | TACR1 355/4885CNR1 543/4885CNR2 846/4885 |
| US-20070149596-A1 | PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | PYCR1, PRMT9, PRLHR | TACR1 80/4885CNR1 125/4885CNR2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.